Literature DB >> 19814969

[Association between endolymphatic hydrops and benign paroxysmal positional vertigo: coincidence or causality?].

Marcos Rossi Izquierdo1, Andrés Soto Varela, Sofía Santos Pérez, Torcuato Labella Caballero.   

Abstract

INTRODUCTION: The aim of this study was to determine the prevalence of benign paroxysmal positional vertigo (BPPV) in patients diagnosed with endolymphatic hydrops (EH) and to analyze whether this association is a factor for poor prognosis in these patients.
MATERIAL AND METHODS: A retrospective study was carried out in our department among the patients definitively diagnosed as having Ménière's disease according to the criteria of the American Academy of Otolaryngology and BPPV by the usual triggering manoeuvres.
RESULTS: The prevalence of BPPV in our patients with EH was 5.1%. The rate of cure with the repositioning manoeuvres is 90.9%, however success with the first manoeuvre was only 63.36%. Recurrences occurred in up to 22.22%. We found a lower success rate with the first manoeuvre in relation to the rest of the patients with BPPV without EH. This difference is statistically significant (P=0.042). DISCUSSION: We did not find that these patients to have a lower rate of cure with the repositioning manoeuvres or a higher rate of recurrence. But in our protocol the first manoeuvre had a lower success rate than in the rest of the patients.

Entities:  

Mesh:

Year:  2009        PMID: 19814969     DOI: 10.1016/j.otorri.2009.02.003

Source DB:  PubMed          Journal:  Acta Otorrinolaringol Esp        ISSN: 0001-6519


  2 in total

Review 1.  Benign paroxysmal positional vertigo in Meniere's disease: systematic review and meta-analysis of frequency and clinical characteristics.

Authors:  Mansur A Kutlubaev; Ying Xu; Jeremy Hornibrook
Journal:  J Neurol       Date:  2019-08-13       Impact factor: 4.849

2.  Benign paroxysmal positional vertigo simultaneously affecting several canals: a 46-patient series.

Authors:  Andrés Soto-Varela; Marcos Rossi-Izquierdo; Sofía Santos-Pérez
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-05-08       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.